The global pharmaceutical industry experienced a 32% drop in company filings mentions of regenerative medicine in Q3 2023 compared with the previous quarter, with the highest share accounted for by Bayer with 560% year-on-year increase, according to GlobalDataâ€™s analysis of over 344 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q3 2023 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, regenerative medicine was one of the most frequently referenced themes in Q3 2023, ranking highest in terms of mentions, ahead of mobile and internet of things, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Bayer had the greatest increase in references for regenerative medicine in Q3 2023, compared with the previous quarter. GlobalData identified 33 regenerative medicine-related sentences in the company's filings - 3% of all sentences - and an increase of 560% in Q3 2023 compared with Q3 2022. Sarepta Therapeuticsâ€™s mentions of regenerative medicine dropped by 40% to 24 and CSLâ€™s by 17% to 21 and Bristol-Myers Squibbâ€™s by 45% to 16.
GlobalDataâ€™s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for regenerative medicine in Q3 2023 was 98.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q3 2023, buy the report here.